tbuckley/cabot-search huggingface dataset:
Body mass index and mortality in men treated for locally advanced prostate cancer: An analysis of RTOG 85–31
Authors: J. A. Efstathiou, K. Bae, W. U. Shipley, G. E. Hanks, M. V. Pilepich, H. M. Sandler, M. R. Smith
Journal: Journal of Clinical Oncology (2007)

5128 Background: Greater body mass index (BMI) is associated with shorter time to prostate-specific antigen (PSA) failure following radical prostatectomy. We investigated whether BMI is associated with prostate cancer-specific mortality (PCSM) in a large randomized trial of men treated with radiation therapy (RT) and androgen deprivation therapy (ADT) for locally advanced prostate cancer. Methods: Between 1987 and 1992, 945 eligible men with locally advanced prostate cancer were enrolled on a phase III trial (RTOG 85- 31) and randomized to RT and immediate goserelin (Arm I) or RT alone followed by goserelin at relapse (Arm II). Height and weight data were available at baseline for 788 (83%) subjects. Cox regression analyses were performed to evaluate the relationships between BMI and all-cause mortality, PCSM, and non-prostate cancer mortality. Covariates included age, race, treatment arm, history of prostatectomy, nodal involvement, Gleason score, clinical stage, and BMI. Results: The 5-year PCSM rate for men with BMI&lt;25kg/m 2 was 6.5%, compared to 13.1% and 12.2% in men with BMI=25-&lt;30 and BMI=30, respectively (Gray’s p=0.005). In multivariable analyses, as shown in the Table , greater BMI was significantly associated with higher PCSM [for BMI=25-&lt;30, hazard ratio (HR) 1.52, 95% confidence interval (CI) 1.02–2.27, p=0.04; for BMI=30, HR 1.65, 95% CI 1.02–2.66, p=0.04]. BMI was not associated with non-prostate cancer or all-cause mortality. Conclusions: Greater baseline BMI is independently associated with higher PCSM in men with locally advanced prostate cancer. Further studies are warranted to evaluate the mechanism(s) for increased mortality and to assess whether weight loss after prostate cancer diagnosis alters disease course. [Table: see text] No significant financial relationships to disclose.
Changes in the kinase expression panel of K562 human leukemia after Avemar treatment
Authors: A. Telekes, E. Rásó
Journal: Journal of Clinical Oncology (2007)

14143 Background: The positive effect of the wheat germ extract Avemar has already been proved in cancer. Compared to the control group significantly longer survival times were achieved in both in vivo experiments and clinical studies. Inhibition of cell growth was also detected in K562 human leukaemia cell line in vitro. Avemar given p.o.(3 g/kg) resulted in significant increase of the survival time compared to the control group (p&lt;0.005 Mann-Whitney) in i.v. implanted K562 xenograft model, which was practically the same as the effect of Gleevec treatment. Since, the mechanism(s) of action of Avemar is still not properly characterized a kinase expression panel in K562 in vitro model was examined. Methods: K562 cells (8x10 5 cell/ml), were treated with Avemar (500 μg/ml) and mRNS from 3–3 parallel samples and their appropriate controls were isolated 24, 48 hours after the treatment and 24 hours after washing the cells previously treated with Avemar for 48 hours. To determine the kinase expression pattern Kinase OpenArray™ plates were used, having over 500 kinase genes with controls in quadruplicates in each plate. Changes in expression was declared if the average value was over 1 (2-fold change in mRNA copy number) and the standard deviation was relatively small (2xSTDEV = AVERAGE). Results: We have found 16 kinases which expression has temporary or durative (maintained for 24 hour after washing) decreased (e.g.: CCL2, ABR, FLT1, EphB6, TGFa) and 30 which expression has increased (e.g.: CPT1B, IRE1, ITK, RON, LTK, EphB2, FASTK). Conclusions: Our result demonstrated that many of the kinases which expression was altered by Avemar treatment is known to participate in cell cycle, cell migration, apoptosis and signal transduction. Thus, our results might shed light on the main mechanism(s) of action of Avemar and raise the possibility to identify the active substance(es) of this natural extract. No significant financial relationships to disclose.
VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage
Authors: Chen-Hsiang Shen, Brandon J. DeKosky, Yicheng Guo, Kai Xu, Ying Gu, Divya Kilam, Sung Hee Ko, Rui Kong, Kevin Liu, Mark K. Louder, Li Ou, Baoshan Zhang, Cara W. Chao, Martin M. Corcoran, Eric Feng, Jesse Huang, Erica Normandin, Sijy O’Dell, Amy Ransier, Reda Rawi, Mallika Sastry, Stephen D. Schmidt, Shuishu Wang, Yiran Wang, Gwo-Yu Chuang, Nicole A. Doria-Rose, Bob Lin, Tongqing Zhou, Eli A. Boritz, Mark Connors, Daniel C. Douek, Gunilla B. Karlsson Hedestam, Zizhang Sheng, Lawrence Shapiro, John R. Mascola, Peter D. Kwong
Journal: Cell Host & Microbe (2020)
Abstract P3-09-18: Immunization of breast cancer patients in combination with standard-of-care chemotherapy: Results of a phase Ib clinical trial
Authors: Issam Makhoul, Fariba Jousheghany, Saddam Mohammed, Eric Siegel, Angela Pennisi, J Thaddeus Beck, Laura Hutchins, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi
Journal: Cancer Research (2020)

Abstract We have developed a peptide mimotope-based cancer vaccine, P10s-PADRE, targeting tumor associated carbohydrate antigens (TACAs). We have previously shown safety, feasibility and induction of immune response in a phase I clinical trial in stage IV breast cancer patients. In the current clinical trial, immunization with P10s-PADRE vaccine is combined with the standard-of-care chemotherapy in neo-adjuvant setting in subjects diagnosed with early stage ER-positive breast cancer. Various schedules (timing of vaccination doses relative to chemo) for combination therapy were tested. Immunological endpoint variable include antibody response and activation of natural killer (NK) cells as tested in peripheral blood mononuclear cells. Tumor size before treatment and after surgery was measured for each subject. The secondary endpoint was pathologic complete response (pCR). We observed induction of antibody response and activation of NK cells independent of each other. Vaccination affected the expression of several NK markers including CD94 and NKp46 as we observed a significant upregulation of NKp46 (median = 1.79, P&amp;lt;0.0001), and CD94 (median = 1.50, P&amp;lt;0.0001) in response to immunization. The data indicate a significant increase in serum IFN-γ (Median=1.74, P=0.0016) upon vaccination. Increase in IFN-γ was positively correlated with increase in both CD69 (r = 0.46, P=0.0321) and NKp46 (r = 0.39, P=0.0763) on CD56-dim NK cells. Tumor shrinkage was associated with an increase in NK cells, upregulation of NKp46 and CD94 molecules, and increase in frequency of NKp46-positive and CD94-positive CD56-dim NK cells. Among 25 subjects enrolled in 5 different immunization schedules, 5 experienced complete eradication of their primary tumors that was associated with vaccine induced increase in the frequency of CD94-positive CD56-dim NK cells (p= 0.0473). The results are intriguing and warrant expansion of the immunologically effective combination schedule to further establish the clinical efficacy along with potential biomarkers of response. Citation Format: Issam Makhoul, Fariba Jousheghany, Saddam Mohammed, Eric Siegel, Angela Pennisi, J Thaddeus Beck, Laura Hutchins, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi. Immunization of breast cancer patients in combination with standard-of-care chemotherapy: Results of a phase Ib clinical trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-09-18.
Depth of injury of Hetter's phenol-croton oil chemical peel formula using 2 different emulsifying agents
Authors: Aline da Silva Justo, Bruna Mikulis Lemes, Bruna Nunes, Kevin Alves Antunes, Bruna Carletto, Adriana Yuriko Koga, Leandro Cavalcante Lipinski, Mario Rodrigues Montemor Netto, Eduardo Bauml Campagnoli, Flávio Luís Beltrame, Carlos Gustavo Wambier
Journal: Journal of the American Academy of Dermatology (2020)
Implemention of a Division of Internal and Hospital Medicine in a free-standing comprehensive cancer center
Authors: R. Gross
Journal: Journal of Clinical Oncology (2007)

17070 Background: In 2004, the Moffitt Cancer Center implemented a Division of Internal and Hospital Medicine. As a free-standing Comprehensive Cancer Center, Moffitt serves complex cancer patients with a wide range of nononcologic medical needs. These co-morbidities had previously been managed through a combination of subspecialty consultations and ‘out-of-specialty‘ care by the attending oncologist or hematologist. With the rapid growth of hospital medicine as an established specialty, Moffitt recognized an opportunity to reduce fragmentation and variation in noncancer care, minimize disruptions to the focused practices of the cancer specialists, cope with resident workload constraints, and enhance efficiency of inpatient care. The institution commited to the establishment of a dedicated internal and hospital medicine program. Methods: The presentation includes a descriptive accounting of this comprehensive project, from initial planning to implementation and consolidation. Scope of services provided, staffing ratios, and unanticipated challenges and opportunities are described. A survey of stakeholder physicians was undertaken to assess perceived value for various aspects of the program. Opportunity for discussion will be provided for those considering implementation of similar services in their host institution. Results: The new program was successfully implemented and is comprised of an active inpatient service, an inpatient consultation service, a high-risk preoperative evaluation and co-management service, a 24-hour urgent care service, and a limited outpatient clinic. There are 5 physicians and 4 midlevel practitioners in the program, which is closely integrated with the internal medicine residency program of the University of South Florida. Conclusions: An Internal and Hospital Medicine program in a free-standing cancer center appears to provide perceived patient care benefits, peer satisfaction, and utilization efficiencies based on initial survey data. No significant financial relationships to disclose.
Primary invasive breast cancer in 104 women: A single-center experience in the years 1995–2005
Authors: M. Beda, C. Ghiotto, U. Basso, M. Stefani, S. Lonardi, M. Bonavina, S. Monfardini
Journal: Journal of Clinical Oncology (2007)

11093 Background: To assess clinical, genetic and biological characteristics of breast cancer (BC) in women £ 35 years followed in a single Institution, along with patterns of disease recurrence and survival. Materials and Methods: All consecutive women £ 35 years with invasive BC registered at our Medical Oncology Department between 1995 and 2005 were enrolled in this retrospective analysis. Genetic testing for BRCA1/2 and P53 started in the year 2000. Results: Out of 4.120 cases, a total of 104 pts were identified, median age 32 years (range 22–35). Median age at menarche was 13 years, 48% were nulliparous. Approximately on third reported oral contraceptive use, while 23% reported a family history of BC. Almost 90% had a self -diagnosis of disease. Modified radical mastectomy was performed in 48%, conservative surgery in 46%, 6 metastatic pts were not operated. Axillary lymph node involvement was present in one half of cases. The prevalent histology was ductal carcinoma, 78% G2-G3, 26% hormone-receptor negative, 43% HER-2 positive. TNM stage was 29% I, 39% II, 22% III, 10% IV. Neo-adjuvant or adjuvant anthracycline based chemotherapy was administered to 86.7% of patients, combined with taxanes in 23% of cases. Twenty-four patients developed amenorrhea after stopping chemotherapy, the other ER/PgR positive patients received LH-RH analogues for 2 years. Tamoxifen was given to all ER/PgR positive patients. Genetic mutational analysis was available in 43 patients, and 9 mutations of BRCA 1 and 4 of BRCA 2 were found; two patients had a p53 mutation and one of them had an overt Li-Fraumeni syndrome. After a median follow-up of 5.5 years, 29 patients (28%) have recurred and 13 (12.5%) have died, with an estimated 5 year-DFS and OS of 82.4% and 87.5%, respectively. Conclusions: Our data confirm the aggressive biological features of BC in very young women. Intensive chemotherapy produces amenorrhea in 31% of cases. The 35% rate of BRCA1/2 or p53 mutation justifies a broader use of genetic testing in such patients in order to evaluate prophylactic measures for the female relatives. No significant financial relationships to disclose.
Selective imaging of solid tumours via the calcium-dependent high-affinity binding of a cyclic octapeptide to phosphorylated Annexin A2
Authors: Duanwen Shen, Baogang Xu, Kexian Liang, Rui Tang, Gail P. Sudlow, Christopher Egbulefu, Kevin Guo, Avik Som, Rebecca Gilson, Dolonchampa Maji, Suman Mondal, LeMoyne Habimana-Griffin, Walter J. Akers, Shunqiang Li, Yang Liu, Sharon Bloch, Sid Kurkure, Zohar Nussinov, Alexander Seidel, Shaw-Wei D. Tsen, Samuel Achilefu
Journal: Nature Biomedical Engineering (2020)
Early Diagnosis of Myocardial Infarction With Point-of-Care High-Sensitivity Cardiac Troponin I
Authors: Jasper Boeddinghaus, Thomas Nestelberger, Luca Koechlin, Desiree Wussler, Pedro Lopez-Ayala, Joan Elias Walter, Valentina Troester, Paul David Ratmann, Funda Seidel, Tobias Zimmermann, Patrick Badertscher, Karin Wildi, Maria Rubini Giménez, Eliska Potlukova, Ivo Strebel, Michael Freese, Òscar Miró, F. Javier Martin-Sanchez, Damian Kawecki, Dagmar I. Keller, Danielle M. Gualandro, Michael Christ, Raphael Twerenbold, Christian Mueller, Mario Meier, Christian Puelacher, Jeanne du Fay de Lavallaz, Nikola Kozhuharov, Katharina Rentsch, Claudia Stelzig, Kathrin Meissner, Caroline Kulangara, Petra Hillinger, Eleni Michou, Dayana Flores, Tobias Reichlin, Beatriz López, Carolina Fuenzalida, Esther Rodriguez Adrada, Eva Ganovská, Jens Lohrmann, Jeffrey Huber, Jana Steude, Andreas Buser, Arnold von Eckardstein, Beata Morawiec, Ewa Nowalany-Kozielska, Piotr Muzyk, Franz Bürgler, Nicolas Geigy
Journal: Journal of the American College of Cardiology (2020)

Until now, high-sensitivity cardiac troponin (hs-cTn) assays were mainly developed for large central laboratory platforms. This study aimed to assess the clinical performance of a point-of-care (POC)-hs-cTnI assay in patients with suspected myocardial infarction (MI). This study enrolled patients presenting to the emergency department with symptoms suggestive of MI. Two cardiologists centrally adjudicated the final diagnosis using all clinical data including cardiac imaging. The primary objective was to directly compare diagnostic accuracy of POC-hs-cTnI-TriageTrue versus best-validated central laboratory assays. Secondary objectives included the derivation and validation of a POC-hs-cTnI-TriageTrue–specific 0/1-h algorithm. MI was the adjudicated final diagnosis in 178 of 1,261 patients (14%). The area under the curve (AUC) for POC-hs-cTnI-TriageTrue at presentation was 0.95 (95% confidence interval [CI]: 0.93 to 0.96) and was at least comparable to hs-cTnT-Elecsys (AUC: 0.94; 95% CI: 0.93 to 0.96; p = 0.213) and hs-cTnI-Architect (AUC: 0.92; 95% CI: 0.90 to 0.93; p < 0.001). A single cutoff concentration <3 ng/l at presentation identified 45% of patients at low risk with a negative predictive value (NPV) of 100% (95% CI: 99.4% to 100%). A single cutoff concentration >60 ng/l identified patients at high risk with a positive predictive value (PPV) of 76.8% (95% CI: 68.9% to 83.6%). The 0/1-h algorithm ruled out 55% of patients (NPV: 100%; 95% CI: 98.8% to 100%), and ruled in 18% of patients (PPV: 76.8%; 95% CI: 67.2% to 84.7%). Ruled-out patients had cumulative event rates of 0% at 30 days and 1.6% at 2 years. This study confirmed these findings in a secondary analysis including hs-cTnI-Architect for central adjudication. The POC-hs-cTnI-TriageTrue assay provides high diagnostic accuracy in patients with suspected MI with a clinical performance that is at least comparable to that of best-validated central laboratory assays. (Advantageous Predictors of Acute Coronary Syndromes Evaluation Study [APACE]; NCT00470587)
Comparison of various breast cancer detection methods with survival rates
Authors: S. Misra, S. Tarr, D. Pratt
Journal: Journal of Clinical Oncology (2007)

17033 Background: The role of mammography (MG) but not of breast self-exam (BSE) and clinical breast exam (CBE) in breast cancer detection and survival is well documented. This study compares the different methods of breast cancer detection and subsequent survival rates, analyzing the differences even within the same stage of the disease. Methods: Retrospective review of 1,259 patients was done using the hospital Tumor Registry data. Only patients with stage I, IIA and IIB are included and were diagnosed between April 1992 to December 2005 with follow up ranging from June 1993 to August 2006. The detection methods studied include BSE, CBE, MG and ultrasonography (USG). Parametric tests were conducted. Results: Mean age of the sample was 62 years (range 24–96). There were 293 BSE, 64 CBE, 885 MG, 17 USG detected breast cancer patients. Mean size of mass at presentation was 19 mm (range 1–110). Mean survival time for patients detected with breast cancer till August 2001 was 76 months (range 1–163). 67% patients survived 5 years or more and 12% survived more than 10 years. Mean survival for BSE/CBE and MG/USG group was 43 and 57 months respectively. This difference in survival is significant p&lt; .05; The average survival time by stages I, IIA, IIB for BSE was 47, 45, 38 months, for CBE it was 43, 39, 51 months, for MG it was 57, 59, 50 months and for USG group it was 52, 47, 95 months respectively. Even within the same stage, the method of detection affected survival with the BSE and CBE group having less survival rates (Tukey Test mean difference 0.54, 95% C.I 42–66 and 0.38, 95% C.I 15–61) respectively than the MG group. Survival time also positively correlated with cancer recurrence (r =.7), family history (r = .06) and negatively correlated with age (r = -.09), size of tumor (r = -.09), estrogen receptor positivity status (r = -.06) all with (p &lt; 0.05). We believe this study underestimates overall survival rate as the last follow up date was taken as an end point and also the survival rates are not disease specific survival. Conclusions: MG/USG group show higher survival rates compared to BSE/CBE across the early stages of breast cancer. Even within the same stage, the method of detection affects survival with MG/USG detected cases having more favorable outcomes. May be our current staging system for breast cancer is inadequate and needs revision. No significant financial relationships to disclose.
Patient and parent longitudinal reports of quality of life in children and adolescents with osteosarcoma
Authors: P. S. Hinds, J. S. Gattuso, C. Billups, C. Rivera, J. Quintana, N. Daw
Journal: Journal of Clinical Oncology (2007)

19562 Children and adolescents being treated for osteosarcoma are likely to experience physical, emotional, functional and possibly cognitive changes during the course of their treatment. The aims of this prospective study were to assess the effect of treatment on patients’ quality of life (QoL) at diagnosis and during therapy, compare patient and parent QoL reports, and examine relationships between patient QoL and tumor histologic response to preoperative chemotherapy and event-free survival (EFS) in children and adolescents in treatment for osteosarcoma. Newly diagnosed patients with localized disease completed three established patient reports (Symptom Distress Scale, and PedsQL v.3 and v.4). Parents completed two parent reports (PedsQL v.3 and v.4). QoL evaluations were done at diagnosis, prior to definitive surgery (Week 12), and postoperatively during treatment (Week 23). Sixty-two of 72 eligible patients and their parents completed QoL measures. Symptom distress (SD) decreased in 85% of patients from baseline to Week 12 (with 8/10 symptoms significantly improved) and from baseline to Week 23 in 74% of patients. Improvements in most domains of the PedsQL v. 3 were noted by patient and parent reports from baseline to Weeks 12 and 23 except for the nausea domain. Patient and parent reports differed, with parents reporting lower QoL scores on v. 3 than did patients, particularly in the domains of treatment anxiety, cognitive problems, and communication. QoL scores did not differ by patient gender but did by age in certain domains. Patients reported significant improvements in physical and emotional functioning from baseline to Weeks 12 and 23 using the PedsQL v.4. Parents reported significant improvements in emotional functioning from baseline to Weeks 12 and 23 using the PedsQL v.4. QoL scores were not associated with tumor histologic response or EFS. Significant improvements in QoL domains and in symptoms from diagnosis to Week 12 and to Week 23 were documented in both patient and parent reports. Treatment contributed to improvements in physical and emotional functioning and in symptoms except for nausea. QoL was not related to histologic response or EFS. No significant financial relationships to disclose.
Abstract P108: Cardiovascular Health Awareness and the Effect of an Educational Intervention on School-aged Children in Calcutta, India
Authors: Madhab Ray, Santanu Guha, Bipasha Ray, Sayan Basu, Meghna Ray, Avik Karak, Paushaly Sau, Antara Pal, Prakash Hazra, Santanu Goswami, Sudipta Chaudhuri, Harry P Selker, Robert Goldberg, Deepak L Bhatt
Journal: Circulation (2020)

Background: India is going through a major economic and epidemiological transition. With the adoption of a Western lifestyle, atherosclerotic cardiovascular disease (CVD) has emerged as the leading cause of death. India is currently the second most populous country with a population of 1.3 billion and two-thirds of this population are less than 35 years of age. As a result, India is facing major challenges in dealing with CVD. Purpose: This study was conducted to assess the level of health awareness of CVD in school-aged children (10 to 16 years) and to evaluate the effect of a brief educational intervention in enhancing the level of awareness with a goal of developing a school-based health education program. Methods: A school-based survey was conducted in Calcutta, India in August, 2018. This involved a pre-evaluation of CVD health awareness, a short presentation on CVD, and a post-evaluation of CVD health awareness. Results: The survey involved 2,564 students from 18 schools (11 girls’, 5 boys’, 2 coeducation). The mean age of participating students was 14.6 years, 72% were girls, 55% of the students were in the 9th grade, 38% were from 10 th grade, and the rest were from a combination of 8 th ,11 th, and 12 th grades. After assessing students’ awareness in six domains with 20 multiple-choice questions, the mean pre-test score was 46.5 (SD ± 13.3) with a maximum score of 100, and the mean post-test score was 53.6 (SD ± 20.6) ( p &lt; 0.001). Conclusions: Awareness of CVD and its risk factors was inadequate among school-aged children in Calcutta. A school-based educational program may promote awareness of CVD and adoption of healthy lifestyle practices. The results of this study may help formulate a nationwide school health program to ameliorate the morbidity and mortality of CVD in India where it has emerged as a modern epidemic.
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
Authors: Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Christian S Frandsen, Julie L Forman, Nicolai J Wewer Albrechtsen, Jens J Holst, Ulrik Pedersen-Bjergaard, Sten Madsbad, Tina Vilsbøll, Henrik U Andersen, Filip K Knop
Journal: The Lancet Diabetes & Endocrinology (2020)